Infant rats were passively immunized to determine the protective capacity of pneumococcal anticapsular antibodies. Animal-passaged strains of Streptococcus pneumoniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f, and 23f were used as challenge inocula (1 -1500 cfu) in a model of pulmonary infection that resulted in bacteremia, meningitis, and death. From untreated control animals, histologic sections of lung demonstrated infiltrative pneumonia and lung homogenate cultures grew S. pneumoniae at concentrations of 10 3 -10 8 cfu per gram of lung tissue. A type-specific anti-capsular antibody serum concentration of 0.1 -1.15 mg/mL resulted in a statistically significant reduction in mortality compared with the reduction in untreated controls, except for serotype 14, which required 2.32 mg/mL for a significant reduction in mortality. The serum antibody level that provided 50% reduction in mortality ranged from 0.1 -3.5 mg/mL for all serotypes.
Worldwide each year, 4 million pediatric deaths are due to bacterial polysaccharide immune globulin (BPIG) containing pneumococcal antibodies protected high-risk Apache children, acute lower respiratory tract infection, Ç40% of which are believed to be due to Streptococcus pneumoniae [1] . In the the minimum serum anticapsular antibody concentrations that are protective against disease are unknown. United States, S. pneumoniae is the most common etiology of bacterial pneumonia. This organism causes 50,000 cases of
We have developed a pulmonary infection model of S. pneumoniae in infant rats [13] that results in bacteremia, meningitis, bacteremia and 3000 cases of meningitis yearly and accounts for 40,000 deaths each year in all age groups [2 -4] . Efforts to and death. In particular, our model uses low levels of challenge inocula of pneumococcal strains prevalent in children in both ameliorate the morbidity and mortality associated with invasive pneumococcal infection have included immunization with developed and underdeveloped countries. Our hypotheses for this study were that infant rats treated with pneumococcal antipolyvalent polysaccharide vaccines. However, polysaccharide vaccines are poorly immunogenic in children õ2 years of age, capsular antibodies against S. pneumoniae (compared with untreated control animals) would be protected against invasive and such children are among those at highest risk [5 -9] . Conjugate pneumococcal vaccines may provide protective immunity infection and death, and that the concentration of antibodies required for protection would be similar among different seroin all age groups, including the young child. Safety and immunogenicity data have been reported [8 -11] , and efficacy trials types. of conjugate vaccines are now underway.
Two important issues are evident regarding the protection afforded by such vaccines. First, unlike conjugate vaccines Materials and Methods directed against Haemophilus influenzae type b, conjugate vacBacteriologic methods. Animal-passaged strains of S. pneucines against S. pneumoniae will need to be immunogenic for moniae serotypes 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f , and 23f were and protective against several serotypes that cause disease in used in our experiments. In previous experiments [13] , we passed humans. Second, although Santosham et al. [12] showed that isolates of S. pneumoniae via intraperitoneal or intrathoracic inoculation. Recovery of an isolate from a bacteremic animal was considered animal passage. Strains were stored in either skim milk or Todd-Hewitt broth supplemented with 0.5% yeast extract (Difco, To assess lung microbiology, we dissected lungs en bloc (in concentrations were 1.25 mg/mL for serotype 14; 2.5 mg/mL for serotypes 4, 9v, and 18c; 5.0 mg/mL for serotypes 1, 5, and 7f; sterile fashion) from the thorax and then transported them in sterile glass vials and weighed and homogenized the specimens, using a and 10 mg/mL for serotypes 6b, 19f, and 23f. microliters of 3-fold serial dilutions of preabsorbed BPIG per well was added in triplicate to antigen-coated microtiter plates and incuCultures of blood and cerebrospinal fluid were performed on 5% sheep blood agar. Cultures of lung homogenate were performed bated for 2 h at room temperature. The plates were washed with 0.01 M PBS-0.1% Tween, and 50 mL of alkaline phosphataseon 5% sheep blood agar supplemented with gentamicin to inhibit the growth of normal flora. Plates were incubated overnight at labeled conjugate goat anti-human IgG (Caltag Laboratory, South San Francisco) was added to each well and incubated for 2 h at 37ЊC, and colonies were counted the following morning.
Animal model. Outbred virus-free Sprague-Dawley rats were room temperature. The wells were washed, and p-nitrophenylphosphate (75 mL/well; Sigma Chemicals, St. Louis) in buffer was obtained from Charles River Laboratories (Wilmington, MA). Pregnant female rats were allowed to deliver in our animal housing added, and the mixture was incubated for 30 min. The reaction was stopped by the addition of 50 mL of 3 N NaOH per well. A 405 units. On day 4 of life, infant pups from all litters were randomly distributed so that each mother had 10-12 pups.
values were determined with an EIA reader (Molecular Devices, Menlo Park, CA). One day prior to challenge with S. pneumoniae, the infant rats were treated with either normal saline or different doses of BPIG On the basis of standard assignments of antibody in antipneumococcal US standard reference serum 89-SF (provided by Carl by subcutaneous administration. BPIG lot 8 (BPIG-8; Massachusetts Biologics Laboratory, Jamaica Plain, MA) is a hyperimmune Frasch, Center for Biological Evaluation and Review, US Food and Drug Administration, Rockville, MD) [14] , serotype-specific globulin obtained from adult humans immunized with 23-valent pneumococcal vaccine, 4-valent meningococcal vaccine, and H.
IgG concentrations were determined for BPIG-8 (table 1) . Serotype specific anti-capsular antibody was measured in the influenzae type b vaccine as described previously [14] . BPIG was administered as a 0.1-mL volume of globulin preparation (1:1) serum samples obtained just prior to S. pneumoniae challenge. An ELISA was performed as above. and as 0.1-mL volumes of 1:5 and 1:25 dilutions. One day later, just prior to S. pneumoniae challenge, tail vein blood was obtained Analysis of data. Differences in mortality rates between untreated control animals and antibody-treated animals were analyzed for determinations of serum concentrations of pneumococcal anticapsular antibody.
by use of Fisher's exact test. P õ.05 was considered significant. Intrathoracic inoculations were then performed in the following fashion. The right chest of each 4-day-old pup was prepared with alcohol, and a 0.025-mL inoculum of S. pneumoniae in 0.5% agar-
Results
ose was injected transthoracically into the mid-right lung via a 29-gauge needle on an insulin syringe. The depth of injection was Animal model. We conducted 73 experiments in which controlled by a small hemostat clipped 3 mm from the needle mortality was ú40% in 43 (59%) of 73 control groups. Mortalbevel. ity in control groups was õ40% in 30 experiments, including
In order to challenge the animals with an inoculum that produced 15 experiments in which mortality was 0% (bacteremia not high rates of bacteremia but one which was not uniformly lethal, detected). These 30 experiments were excluded in order to we administered to the infant rats either a ''low'' or a ''high'' analyze the 43 experiments in which the control mortality redose, as determined on the basis of our previous experiments, of S. pneumoniae [13] . These doses typically differed by one logarithm (e.g., 10 cfu and 100 cfu/dose) and corresponded to the bacterial inoculum that produced Ç50% and 90% bacteremia, respectively, Table 1 . Mean ({SD) concentrations (mg/mL) of IgG anti-capsular antibody in the standard human antipneumococcal reference serum, in control groups. The bacterial challenge that resulted in this rate lot 89-SF, and in bacterial polysaccharide immune globulin lot 8 of bacteremia ranged from 1 to 1500 cfu per inoculum. In this (BPIG-8). model, death uniformly followed bacteremia within Ç24 h.
Blood and cerebrospinal fluid were cultured 1, 2, and 3 days Streptococcus after inoculation as previously described [13] . Mortality was as- flected the delivery of an adequate inoculum, which had been mean ratio of antibody concentration in serum at 24 h:antibody concentration in BPIG was 0.249 for serum samples in the estimated from the optical density readings.
Animal model: bacteriologic and histologic results. Serosubgroup. This ratio predicts the concentration of antibody that will be present in the serum 24 h after a 0.1-mL subcutaneous types 1, 4, 5, 6b, 7f, 9v, 14, 18c, 19f , and 23f were used as intrapulmonary challenge. As we found in a previous study dose of BPIG prior to S. pneumoniae challenge.
Protective effect of pneumococcal anti-capsular antibodies [13] , animals whose blood sample cultures grew S. pneumoniae died the day after challenge, and 20% -50% of bacteremic against S. pneumoniae challenge. In our model, a proportion of bacteremic animals had S. pneumoniae isolated from the animals had S. pneumoniae isolated from cerebrospinal fluid.
Histologic sections of lung from untreated control animals cerebrospinal fluid, and all bacteremic animals died. Thus, protection from bacteremia resulted in protection from meningitis infected with 4 serotypes (1, 6b, 19f, 23f ) demonstrated similar pathology, consisting of polymorphonuclear and leukocyte inand death. Administration of increasing doses of BPIG resulted in a reduction in bacteremia, meningitis, and mortality in filtration at the site of lung puncture and patchy infiltrative consolidation of lung parenchyma (figure 1). Lung homogenate treated versus control animals challenged with S. pneumoniae (table 3) . Lung histology preparations from infected animals cultures demonstrated growth of corresponding S. pneumoniae types at concentrations of 10 3 to 10 8 cfu per gram of lung treated with anti-capsular antibody were normal (figure 1), and lung homogenate cultures were sterile. tissue, confirming a replicating focus of infection.
Quantitation of serum anti-capsular antibody concentrations
A type-specific anti-capsular antibody serum concentration of 0.10 -1.15 mg/mL resulted in a statistically significant reducin treated animals. Blood obtained from treated animals for determination of type-specific antibody concentrations was astion in mortality compared with mortality in untreated controls, except for serotype 14, which required 2.32 mg/mL for a sigsayed for anticapsular antibody to types 6b, 14, 18c, 19f , and 23f, as described above. By comparing serum levels from this nificant reduction in mortality (table 3) . We also plotted the mean serum type-specific anti-capsular subgroup to the type-specific antibody concentrations in the globulin preparation, we calculated a volume of distribution antibody concentrations against the relative reduction in mortality (the difference between control and treatment group morfor human IgG antibody in infant rats (table 2). The geometric tality divided by control group mortality). Figure 2 shows that increasing serum levels of anti-capsular antibody results in increased reduction in mortality. The serum level that provided Table 2 . Ratio of measured serum type -specific anticapsular antiincreases in relative reduction in mortality varied for different body concentration (mg/mL) to the mean serum concentration (mg/ mL) of type-specifc antibody in immune globulin preparation after a serotypes. On the basis of interpolation of our data, the serum 0.1-mL subcutaneous dose of bacterial polysaccharide immune globuantibody level that provided 50% reduction in mortality ranged lin.
from 0.1 to 3.5 mg/mL. tically significant reduction in mortality for all serotypes except * Geometric mean ratio for serotypes Å 0.249. type 14, which appears to require slightly higher serum levels.
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We found that animals treated with anti-capsular antibody was reported with a serum level of 2.6 mg/mL for serotype 4, whereas a similar efficacy of 62% corresponded to a serum were protected against pneumonia, bacteremia, meningitis, and death. In particular, lung histology clearly demonstrated that concentration of 14.8 mg/mL for serotype 14.
It is not known if these antibody concentrations will correlate antibody-treated animals had no evidence of pneumonia. In addition, S. pneumoniae was not isolated from cultures of lung with protection against pneumococcal disease in humans. Antibodies to polyribophosphate, the capsular polysaccharide of H. homogenate from antibody-treated animals. Rats without pneumonia did not develop bacteremia, and therefore meningitis influenzae type b (Hib), were protective against bacteremia and meningitis in an infant rat model of Hib infection [17] . In fact, and death were prevented in treated animals.
That the anticapsular antibody concentration that provides the protective level of anti-polyribophosphate in this model was found to be §150 ng/mL, which was similar to the protecprotection against serotype 14 may be higher than that for other serotypes has been noted by other investigators. Wenger et al.
tive level for humans. Protection from S. pneumoniae infection in mice by passive [16] have reported differences in protective efficacy for a 7-valent capsular pneumococcal vaccine among different serotransfer of antibody was studied by Katz and et al. [18] as part of an effort to evaluate an RIA for measurement of serum types. In particular, for example, a protective efficacy of 76% 
